Peter A. Jones, Ph.D.
Alan F. List, M.D.
Edward A. Sausville, M.D., Ph.D.
Howard I. Scher, M.D.
Daniel D. Von Hoff, M.D.

Peter A. Jones, Ph.D.
Director of the USC/Norris Comprehensive Cancer Center, Distinguished Professor of Urology, Biochemistry and Molecular Biology, Keck School of Medicine at the University of Southern California and is currently President of the American Association for Cancer Research (AACR). Dr. Jones is a pioneer in the study of DNA methylation in human cancer, a process associated with controlling tumor suppressor genes in a wide variety of tumors.

Alan F. List, M.D.
Chief of the Hematologic Division at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, and Professor of Medicine and Oncology at the University of South Florida College of Medicine. Dr. List is an internationally recognized investigator in the biology and treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). He serves on the Board of Directors for the MDS Foundation and the Aplastic Anemia and MDS International Foundation.

Edward A. Sausville, M.D., Ph.D.
Associate Director for Clinical Research, Greenebaum Cancer Center, University of Maryland. Dr. Sausville has served as associate director of the National Cancer Institute's Developmental Therapeutics Program, which has played a key role in developing many currently used anti-cancer drugs.

Howard I. Scher, M.D.
Chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan Kettering Cancer Center, New York, where he oversees development of new therapies for prostate cancer, including the use of monoclonal antibodies, vaccines, and drugs that target specific signaling pathways. Dr. Scher is widely renowned in the field of genitourinary cancers.

Daniel D. Von Hoff, M.D.
Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He also is Chief Scientific Officer for US Oncology. Dr. Von Hoff and his colleagues were involved in the beginning of the development of many of anti-cancer agents including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, and CPT-11. He was appointed by the President to the National Cancer Advisory Board. He is past President of the American Association for Cancer Research, a founder of ILEX™ Oncology, Inc. (recently acquired by Genzyme), founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents, and Editor-in-Chief of Molecular Cancer Therapeutics.